vusolimogene oderparepvec-wtpg

Tudriqev (vusolimogene oderparepvec-wtpg) is a genetically modified oncolytic viral therapy based on a proprietary strain of herpes simplex virus type 1 (HSV-1). Developed by Replimune, it is engineered to selectively replicate in tumor cells, leading to direct oncolysis and the induction of a systemic anti-tumor immune response. The virus is modified by the deletion of the ICP34.5 and ICP47 genes to enhance tumor selectivity and antigen presentation, and it is armed with transgenes for a fusogenic protein (GALV-GP R⁻) to increase cell killing and GM-CSF to stimulate dendritic cell activity. It is indicated for the treatment of adult patients with unresectable advanced cutaneous melanoma who have progressed on PD-1-blocking therapies, typically administered via intratumoral injection in combination with nivolumab.

Brand names

Tudriqev

Other names

vusolimogene oderparepvec